Skip to main content
Top
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Wdr66 is a novel marker for risk stratification and involved in epithelial-mesenchymal transition of esophageal squamous cell carcinoma

Authors: Qing Wang, Chenming Ma, Wolfgang Kemmner

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

We attempted to identify novel biomarkers and therapeutic targets for esophageal squamous cell carcinoma by gene expression profiling of frozen esophageal squamous carcinoma specimens and examined the functional relevance of a newly discovered marker gene, WDR66.

Methods

Laser capture microdissection technique was applied to collect the cells from well-defined tumor areas in collaboration with an experienced pathologist. Whole human gene expression profiling of frozen esophageal squamous carcinoma specimens (n = 10) and normal esophageal squamous tissue (n = 18) was performed using microarray technology. A gene encoding WDR66, WD repeat-containing protein 66 was significantly highly expressed in esophageal squamous carcinoma specimens. Microarray results were validated by quantitative real-time polymerase chain reaction (qRT-PCR) in a second and independent cohort (n = 71) consisting of esophageal squamous cell carcinoma (n = 25), normal esophagus (n = 11), esophageal adenocarcinoma (n = 13), gastric adenocarcinoma (n = 15) and colorectal cancers (n = 7). In order to understand WDR66’s functional relevance siRNA-mediated knockdown was performed in a human esophageal squamous cell carcinoma cell line, KYSE520 and the effects of this treatment were then checked by another microarray analysis.

Results

High WDR66 expression was significantly associated with poor overall survival (P = 0.031) of patients suffering from esophageal squamous carcinomas. Multivariate Cox regression analysis revealed that WDR66 expression remained an independent prognostic factor (P = 0.042). WDR66 knockdown by RNA interference resulted particularly in changes of the expression of membrane components. Expression of vimentin was down regulated in WDR66 knockdown cells while that of the tight junction protein occludin was markedly up regulated. Furthermore, siRNA-mediated knockdown of WDR66 resulted in suppression of cell growth and reduced cell motility.

Conclusions

WDR66 might be a useful biomarker for risk stratification of esophageal squamous carcinomas. WDR66 expression is likely to play an important role in esophageal squamous cell carcinoma growth and invasion as a positive modulator of epithelial-mesenchymal transition. Furthermore, due to its high expression and possible functional relevance, WDR66 might be a novel drug target for the treatment of squamous carcinoma.
Appendix
Available only for authorised users
Literature
1.
go back to reference Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 2012, 62: 10-29. 10.3322/caac.20138.CrossRefPubMed Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 2012, 62: 10-29. 10.3322/caac.20138.CrossRefPubMed
2.
go back to reference Chen Y, Fu D, Xi J, Ji Z, Liu T, Ma Y, Zhao Y, Dong L, Wang Q, Shen X: Expression and clinical significance of UCH37 in human esophageal squamous cell carcinoma. Dig Dis Sci. 2012, 57: 2310-2317. 10.1007/s10620-012-2181-9.CrossRefPubMed Chen Y, Fu D, Xi J, Ji Z, Liu T, Ma Y, Zhao Y, Dong L, Wang Q, Shen X: Expression and clinical significance of UCH37 in human esophageal squamous cell carcinoma. Dig Dis Sci. 2012, 57: 2310-2317. 10.1007/s10620-012-2181-9.CrossRefPubMed
3.
go back to reference Kausar T, Ahsan A, Hasan MR, Lin L, Beer DG, Ralhan R: Sperm protein 17 is a novel marker for predicting cisplatin response in esophageal squamous cancer cell lines. Int J Cancer. 2010, 126: 1494-1503.PubMed Kausar T, Ahsan A, Hasan MR, Lin L, Beer DG, Ralhan R: Sperm protein 17 is a novel marker for predicting cisplatin response in esophageal squamous cancer cell lines. Int J Cancer. 2010, 126: 1494-1503.PubMed
4.
go back to reference Qin YR, Tang H, Xie F, Liu H, Zhu Y, Ai J, Chen L, Li Y, Kwong DL, Fu L, Guan XY: Characterization of tumor-suppressive function of SOX6 in human esophageal squamous cell carcinoma. Clin Cancer Res. 2011, 17: 46-55. 10.1158/1078-0432.CCR-10-1155.CrossRefPubMed Qin YR, Tang H, Xie F, Liu H, Zhu Y, Ai J, Chen L, Li Y, Kwong DL, Fu L, Guan XY: Characterization of tumor-suppressive function of SOX6 in human esophageal squamous cell carcinoma. Clin Cancer Res. 2011, 17: 46-55. 10.1158/1078-0432.CCR-10-1155.CrossRefPubMed
5.
go back to reference Yamasaki M, Makino T, Masuzawa T, Kurokawa Y, Miyata H, Takiguchi S, Nakajima K, Fujiwara Y, Matsuura N, Mori M, Doki Y: Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma. Br J Cancer. 2011, 104: 707-713. 10.1038/sj.bjc.6606071.CrossRefPubMedPubMedCentral Yamasaki M, Makino T, Masuzawa T, Kurokawa Y, Miyata H, Takiguchi S, Nakajima K, Fujiwara Y, Matsuura N, Mori M, Doki Y: Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma. Br J Cancer. 2011, 104: 707-713. 10.1038/sj.bjc.6606071.CrossRefPubMedPubMedCentral
6.
go back to reference Fong HK, Hurley JB, Hopkins RS, Miake-Lye R, Johnson MS, Doolittle RF, Simon MI: Repetitive segmental structure of the transducin beta subunit: homology with the CDC4 gene and identification of related mRNAs. Proc Natl Acad Sci USA. 1986, 83: 2162-2166. 10.1073/pnas.83.7.2162.CrossRefPubMedPubMedCentral Fong HK, Hurley JB, Hopkins RS, Miake-Lye R, Johnson MS, Doolittle RF, Simon MI: Repetitive segmental structure of the transducin beta subunit: homology with the CDC4 gene and identification of related mRNAs. Proc Natl Acad Sci USA. 1986, 83: 2162-2166. 10.1073/pnas.83.7.2162.CrossRefPubMedPubMedCentral
7.
go back to reference Li D, Roberts R: WD-repeat proteins: structure characteristics, biological function, and their involvement in human diseases. Cell Mol Life Sci. 2001, 58: 2085-2097. 10.1007/PL00000838.CrossRefPubMed Li D, Roberts R: WD-repeat proteins: structure characteristics, biological function, and their involvement in human diseases. Cell Mol Life Sci. 2001, 58: 2085-2097. 10.1007/PL00000838.CrossRefPubMed
8.
go back to reference Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith HO, Yandell M, Evans CA, Holt RA: The sequence of the human genome. Science. 2001, 291: 1304-1351. 10.1126/science.1058040.CrossRefPubMed Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith HO, Yandell M, Evans CA, Holt RA: The sequence of the human genome. Science. 2001, 291: 1304-1351. 10.1126/science.1058040.CrossRefPubMed
9.
go back to reference Frydman J, Nimmesgern E, Ohtsuka K, Hartl FU: Folding of nascent polypeptide chains in a high molecular mass assembly with molecular chaperones. Nature. 1994, 370: 111-117. 10.1038/370111a0.CrossRefPubMed Frydman J, Nimmesgern E, Ohtsuka K, Hartl FU: Folding of nascent polypeptide chains in a high molecular mass assembly with molecular chaperones. Nature. 1994, 370: 111-117. 10.1038/370111a0.CrossRefPubMed
10.
go back to reference Kudo Y, Guardavaccaro D, Santamaria PG, Koyama-Nasu R, Latres E, Bronson R, Yamasaki L, Pagano M: Role of F-box protein betaTrcp1 in mammary gland development and tumorigenesis. Mol Cell Biol. 2004, 24: 8184-8194. 10.1128/MCB.24.18.8184-8194.2004.CrossRefPubMedPubMedCentral Kudo Y, Guardavaccaro D, Santamaria PG, Koyama-Nasu R, Latres E, Bronson R, Yamasaki L, Pagano M: Role of F-box protein betaTrcp1 in mammary gland development and tumorigenesis. Mol Cell Biol. 2004, 24: 8184-8194. 10.1128/MCB.24.18.8184-8194.2004.CrossRefPubMedPubMedCentral
11.
go back to reference Silva FP, Hamamoto R, Nakamura Y, Furukawa Y: WDRPUH, a novel WD-repeat-containing protein, is highly expressed in human hepatocellular carcinoma and involved in cell proliferation. Neoplasia. 2005, 7: 348-355. 10.1593/neo.04544.CrossRefPubMedPubMedCentral Silva FP, Hamamoto R, Nakamura Y, Furukawa Y: WDRPUH, a novel WD-repeat-containing protein, is highly expressed in human hepatocellular carcinoma and involved in cell proliferation. Neoplasia. 2005, 7: 348-355. 10.1593/neo.04544.CrossRefPubMedPubMedCentral
12.
go back to reference Meisinger C, Prokisch H, Gieger C, Soranzo N, Mehta D, Rosskopf D, Lichtner P, Klopp N, Stephens J, Watkins NA: A genome-wide association study identifies three loci associated with mean platelet volume. Am J Hum Genet. 2009, 84: 66-71. 10.1016/j.ajhg.2008.11.015.CrossRefPubMedPubMedCentral Meisinger C, Prokisch H, Gieger C, Soranzo N, Mehta D, Rosskopf D, Lichtner P, Klopp N, Stephens J, Watkins NA: A genome-wide association study identifies three loci associated with mean platelet volume. Am J Hum Genet. 2009, 84: 66-71. 10.1016/j.ajhg.2008.11.015.CrossRefPubMedPubMedCentral
13.
go back to reference Akdi A, Gimenez EM, Garcia-Quispes W, Pastor S, Castell J, Biarnes J, Marcos R, Velazquez A: WDR3 gene haplotype is associated with thyroid cancer risk in a Spanish population. Thyroid. 2010, 20: 803-809. 10.1089/thy.2010.0072.CrossRefPubMed Akdi A, Gimenez EM, Garcia-Quispes W, Pastor S, Castell J, Biarnes J, Marcos R, Velazquez A: WDR3 gene haplotype is associated with thyroid cancer risk in a Spanish population. Thyroid. 2010, 20: 803-809. 10.1089/thy.2010.0072.CrossRefPubMed
14.
go back to reference Sato N, Koinuma J, Fujita M, Hosokawa M, Ito T, Tsuchiya E, Kondo S, Nakamura Y, Daigo Y: Activation of WD repeat and high-mobility group box DNA binding protein 1 in pulmonary and esophageal carcinogenesis. Clin Cancer Res. 2010, 16: 226-239. 10.1158/1078-0432.CCR-09-1405.CrossRefPubMed Sato N, Koinuma J, Fujita M, Hosokawa M, Ito T, Tsuchiya E, Kondo S, Nakamura Y, Daigo Y: Activation of WD repeat and high-mobility group box DNA binding protein 1 in pulmonary and esophageal carcinogenesis. Clin Cancer Res. 2010, 16: 226-239. 10.1158/1078-0432.CCR-09-1405.CrossRefPubMed
15.
go back to reference Kemmner W, Kessel P, Sanchez-Ruderisch H, Moller H, Hinderlich S, Schlag PM, Detjen K: Loss of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE) induces apoptotic processes in pancreatic carcinoma cells. FASEB J. 2012, 26: 938-946. 10.1096/fj.11-186700.CrossRefPubMed Kemmner W, Kessel P, Sanchez-Ruderisch H, Moller H, Hinderlich S, Schlag PM, Detjen K: Loss of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE) induces apoptotic processes in pancreatic carcinoma cells. FASEB J. 2012, 26: 938-946. 10.1096/fj.11-186700.CrossRefPubMed
16.
go back to reference Kretschmer C, Sterner-Kock A, Siedentopf F, Schoenegg W, Schlag PM, Kemmner W: Identification of early molecular markers for breast cancer. Mol Cancer. 2011, 10: 15-10.1186/1476-4598-10-15.CrossRefPubMedPubMedCentral Kretschmer C, Sterner-Kock A, Siedentopf F, Schoenegg W, Schlag PM, Kemmner W: Identification of early molecular markers for breast cancer. Mol Cancer. 2011, 10: 15-10.1186/1476-4598-10-15.CrossRefPubMedPubMedCentral
17.
go back to reference Hofmann O, Caballero OL, Stevenson BJ, Chen YT, Cohen T, Chua R, Maher CA, Panji S, Schaefer U, Kruger A: Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci USA. 2008, 105: 20422-20427. 10.1073/pnas.0810777105.CrossRefPubMedPubMedCentral Hofmann O, Caballero OL, Stevenson BJ, Chen YT, Cohen T, Chua R, Maher CA, Panji S, Schaefer U, Kruger A: Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci USA. 2008, 105: 20422-20427. 10.1073/pnas.0810777105.CrossRefPubMedPubMedCentral
18.
go back to reference Ghafouri-Fard S, Modarressi MH: Expression of cancer-testis genes in brain tumors: implications for cancer immunotherapy. Immunotherapy. 2012, 4: 59-75. 10.2217/imt.11.145.CrossRefPubMed Ghafouri-Fard S, Modarressi MH: Expression of cancer-testis genes in brain tumors: implications for cancer immunotherapy. Immunotherapy. 2012, 4: 59-75. 10.2217/imt.11.145.CrossRefPubMed
19.
go back to reference Forghanifard MM, Gholamin M, Farshchian M, Moaven O, Memar B, Forghani MN, Dadkhah E, Naseh H, Moghbeli M, Raeisossadati R, Abbaszadegan MR: Cancer-testis gene expression profiling in esophageal squamous cell carcinoma: identification of specific tumor marker and potential targets for immunotherapy. Cancer Biol Ther. 2011, 12: 191-197. 10.4161/cbt.12.3.15949.CrossRefPubMed Forghanifard MM, Gholamin M, Farshchian M, Moaven O, Memar B, Forghani MN, Dadkhah E, Naseh H, Moghbeli M, Raeisossadati R, Abbaszadegan MR: Cancer-testis gene expression profiling in esophageal squamous cell carcinoma: identification of specific tumor marker and potential targets for immunotherapy. Cancer Biol Ther. 2011, 12: 191-197. 10.4161/cbt.12.3.15949.CrossRefPubMed
20.
go back to reference Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, Jungbluth A, Gnjatic S, Thompson JA, Yee C: Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med. 2008, 358: 2698-2703. 10.1056/NEJMoa0800251.CrossRefPubMedPubMedCentral Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, Jungbluth A, Gnjatic S, Thompson JA, Yee C: Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med. 2008, 358: 2698-2703. 10.1056/NEJMoa0800251.CrossRefPubMedPubMedCentral
21.
go back to reference Junqueira C, Guerrero AT, Galvao-Filho B, Andrade WA, Salgado AP, Cunha TM, Ropert C, Campos MA, Penido ML, Mendonca-Previato L: Trypanosoma cruzi adjuvants potentiate T cell-mediated immunity induced by a NY-ESO-1 based antitumor vaccine. PLoS One. 2012, 7: e36245-10.1371/journal.pone.0036245.CrossRefPubMedPubMedCentral Junqueira C, Guerrero AT, Galvao-Filho B, Andrade WA, Salgado AP, Cunha TM, Ropert C, Campos MA, Penido ML, Mendonca-Previato L: Trypanosoma cruzi adjuvants potentiate T cell-mediated immunity induced by a NY-ESO-1 based antitumor vaccine. PLoS One. 2012, 7: e36245-10.1371/journal.pone.0036245.CrossRefPubMedPubMedCentral
22.
go back to reference Weide B, Zelba H, Derhovanessian E, Pflugfelder A, Eigentler TK, Di Giacomo AM, Maio M, Aarntzen EH, de Vries IJ, Sucker A: Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol. 2012, 30: 1835-1841. 10.1200/JCO.2011.40.2271.CrossRefPubMed Weide B, Zelba H, Derhovanessian E, Pflugfelder A, Eigentler TK, Di Giacomo AM, Maio M, Aarntzen EH, de Vries IJ, Sucker A: Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol. 2012, 30: 1835-1841. 10.1200/JCO.2011.40.2271.CrossRefPubMed
23.
go back to reference Vuoriluoto K, Haugen H, Kiviluoto S, Mpindi JP, Nevo J, Gjerdrum C, Tiron C, Lorens JB, Ivaska J: Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene. 2011, 30: 1436-1448. 10.1038/onc.2010.509.CrossRefPubMed Vuoriluoto K, Haugen H, Kiviluoto S, Mpindi JP, Nevo J, Gjerdrum C, Tiron C, Lorens JB, Ivaska J: Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene. 2011, 30: 1436-1448. 10.1038/onc.2010.509.CrossRefPubMed
24.
go back to reference Kahlert C, Lahes S, Radhakrishnan P, Dutta S, Mogler C, Herpel E, Brand K, Steinert G, Schneider M, Mollenhauer M: Overexpression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitro. Clin Cancer Res. 2011, 17: 7654-7663. 10.1158/1078-0432.CCR-10-2816.CrossRefPubMed Kahlert C, Lahes S, Radhakrishnan P, Dutta S, Mogler C, Herpel E, Brand K, Steinert G, Schneider M, Mollenhauer M: Overexpression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitro. Clin Cancer Res. 2011, 17: 7654-7663. 10.1158/1078-0432.CCR-10-2816.CrossRefPubMed
25.
go back to reference Mendez MG, Kojima S, Goldman RD: Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. FASEB J. 2010, 24: 1838-1851. 10.1096/fj.09-151639.CrossRefPubMedPubMedCentral Mendez MG, Kojima S, Goldman RD: Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. FASEB J. 2010, 24: 1838-1851. 10.1096/fj.09-151639.CrossRefPubMedPubMedCentral
26.
go back to reference Gockel I, Sgourakis G, Lyros O, Polotzek U, Schimanski CC, Lang H, Hoppo T, Jobe BA: Risk of lymph node metastasis in submucosal esophageal cancer: a review of surgically resected patients. Expert Rev Gastroenterol Hepatol. 2011, 5: 371-384. 10.1586/egh.11.33.CrossRefPubMed Gockel I, Sgourakis G, Lyros O, Polotzek U, Schimanski CC, Lang H, Hoppo T, Jobe BA: Risk of lymph node metastasis in submucosal esophageal cancer: a review of surgically resected patients. Expert Rev Gastroenterol Hepatol. 2011, 5: 371-384. 10.1586/egh.11.33.CrossRefPubMed
27.
go back to reference Sung CO, Han SY, Kim SH: Low expression of claudin-4 is associated with poor prognosis in esophageal squamous cell carcinoma. Ann Surg Oncol. 2011, 18: 273-281. 10.1245/s10434-010-1289-4.CrossRefPubMed Sung CO, Han SY, Kim SH: Low expression of claudin-4 is associated with poor prognosis in esophageal squamous cell carcinoma. Ann Surg Oncol. 2011, 18: 273-281. 10.1245/s10434-010-1289-4.CrossRefPubMed
Metadata
Title
Wdr66 is a novel marker for risk stratification and involved in epithelial-mesenchymal transition of esophageal squamous cell carcinoma
Authors
Qing Wang
Chenming Ma
Wolfgang Kemmner
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-137

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine